Matt Larew
Stock Analyst at William Blair
(0.62)
# 4,114
Out of 5,105 analysts
14
Total ratings
44.44%
Success rate
-21.25%
Average return
Main Sectors:
Stocks Rated by Matt Larew
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Upgrades: Outperform | n/a | $193.03 | - | 1 | Oct 6, 2025 | |
| TMO Thermo Fisher Scientific | Initiates: Outperform | n/a | $572.28 | - | 1 | Aug 19, 2025 | |
| MXCT MaxCyte | Downgrades: Market Perform | n/a | $1.52 | - | 2 | Aug 7, 2025 | |
| MRVI Maravai LifeSciences Holdings | Downgrades: Market Perform | n/a | $3.60 | - | 1 | Nov 8, 2024 | |
| DNA Ginkgo Bioworks Holdings | Downgrades: Underperform | n/a | $9.34 | - | 3 | May 10, 2024 | |
| ATR AptarGroup | Upgrades: Outperform | n/a | $121.47 | - | 1 | Apr 29, 2024 | |
| TECH Bio-Techne | Initiates: Outperform | n/a | $58.51 | - | 1 | Aug 28, 2023 | |
| AVTR Avantor | Downgrades: Market Perform | n/a | $11.17 | - | 1 | Jul 31, 2023 | |
| INNV InnovAge Holding | Downgrades: Market Perform | n/a | $5.40 | - | 2 | Sep 22, 2021 | |
| TWST Twist Bioscience | Initiates: Outperform | n/a | $30.93 | - | 1 | Jun 29, 2021 |
Charles River Laboratories International
Oct 6, 2025
Upgrades: Outperform
Price Target: n/a
Current: $193.03
Upside: -
Thermo Fisher Scientific
Aug 19, 2025
Initiates: Outperform
Price Target: n/a
Current: $572.28
Upside: -
MaxCyte
Aug 7, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.52
Upside: -
Maravai LifeSciences Holdings
Nov 8, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $3.60
Upside: -
Ginkgo Bioworks Holdings
May 10, 2024
Downgrades: Underperform
Price Target: n/a
Current: $9.34
Upside: -
AptarGroup
Apr 29, 2024
Upgrades: Outperform
Price Target: n/a
Current: $121.47
Upside: -
Bio-Techne
Aug 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $58.51
Upside: -
Avantor
Jul 31, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $11.17
Upside: -
InnovAge Holding
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $5.40
Upside: -
Twist Bioscience
Jun 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $30.93
Upside: -